<DOC>
	<DOCNO>NCT02234687</DOCNO>
	<brief_summary>In study , propose employ randomize , double-blind , placebo-controlled , outpatient clinical trial test efficacy , safety , tolerability 160 mg 40 mg challenge mGlu2/3 agonist pomaglumetad methionil relative placebo modulate fear-potentiated startle response behavior adult post-traumatic stress disorder ( PTSD ) ( N=30 ) . Each participant receive single dose study drug ( 40 mg v 160 mg v placebo 1:1:1 ratio ) .</brief_summary>
	<brief_title>A mGlu2/3 Agonist Treatment PTSD</brief_title>
	<detailed_description />
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<criteria>Men woman 18 60 year age , race Primary , current Axis I diagnosis post traumatic stress disorder ( PTSD ) accord Diagnostic Statistical Manual Mental Disorders IV ( DSMIV ) criteria Able provide write informed consent Past current presence psychotic symptom , diagnosis lifetime psychotic disorder include schizophrenia , schizoaffective disorder , bipolar disorder History moderate severe traumatic brain injury ( TBI ) loss consciousness Lifetime history seizure disorder Current diagnosis obsessivecompulsive disorder ( OCD ) Current diagnosis bulimia nervosa anorexia nervosa ; substance use disorder Alcohol drug abuse past 90 day , dependence past year . Individuals cumulative lifetime history intravenous substance abuse longer 1 year . Severe dissociation , define Clinician Administered Dissociative States Scale ( CADSS ) score great 60 baseline Patients creatinine clearance &lt; 60 milliliter ( mL ) /min ( moderate renal impairment ) Current pregnancy breast feeding ; medical condition could interfere correct interpretation study data , i.e. , individual follow medical condition exclude : cancer past year , stroke , heart attack , angina , neurological disease ( multiple sclerosis , epilepsy , Parkinson 's disease ) , central nervous system ( CNS ) lesion include TBI loss consciousness , dementing illness , and/or liver kidney disease . Patients QT interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) . Participants start new medication regimen PTSD within 3 month prior study start subject take fluoxetine Current suicidality define emergent Columbia Suicide Severity Rating Scale ( CSSRS ) define suicidal behavior , suicidal ideation score 5 ( indicate active suicidal ideation specific plan level intent ) 4 ( indicate active suicidal ideation intent act , without specific plan ) CSSRS absence CSSRS suicidal ideation score 5 4 CSSRSdefined suicidal behavior , investigator determines patient significant shortterm risk suicide attempt . Individuals active suicidal risk , active selfmutilation aggressive behavior threaten behavior toward others within past year , judge Principal Investigator Pregnant lactate woman Legal Financial : Current legal proceeding result traumatic event . People whose continued receipt financial benefit contingent upon maintain PTSD symptom wait decision concern receipt financial benefit base upon PTSD symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>post-traumatic stress disorder</keyword>
</DOC>